Kourtney Kardashian’s new “GLP-1 Daily” pill is the latest product to capitalize on the weight loss drug craze.

One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker medical awards recognize a trio of scientists without whom Ozempic and other blockbuster weight-loss drugs might not exist.

Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic—so what was that journey like for the scientists involved?

F ROM LOS ANGELES to London, weight-loss drugs such as Ozempic are reshaping culture as much as waistlines. Some Ozempic-takers have tiny appetites and dine at unusual hours to avoid spells of nausea.

In July, the U.S. Food and Drug Administration warned that people are overdosing on compounded semaglutide injectable products.

Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in recent years.

Meaning, whether you lose weight through a change in your diet, a different medication, or bariatric surgery, there is a risk of losing bone density. However, in this particular study, taking weight loss drugs like Ozempic did seem to have a bigger impact on bone density than losing weight through other means.

Four key factors can greatly impact how much weight people lose while taking GLP-1 drugs like Ozempic, Wegovy, Victoza, and Saxenda. Here's what to know.